Gabriela Cinat

Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial

Michele Maio, Karl D. Lewis, Lev Demidov et al. · The Lancet Oncology · 2018 · 210 citations · Full text

Medicine, Melanoma, Immunology +10

MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial

Brigitte Dréno, John F Thompson, B. Mark Smithers et al. · The Lancet Oncology · 2018 · 190 citations

Tumor Immunology, Cancer Immunosurveillance, Medicine +11

Cellular and Humoral Immune Response to N-Glycolyl-GM3 Elicited by Prolonged Immunotherapy With an Anti-Idiotypic Vaccine in High-Risk and Metastatic Breast Cancer Patients

Marcelo D. Guthmann, M. Castro, Gabriela Cinat et al. · Journal of Immunotherapy · 2006 · 58 citations

Immunology, Immunotherapeutics, N-glycolyl-gm3 Elicited +21

Access to innovative medicines for metastatic melanoma worldwide: Melanoma World Society and European Association of Dermato-oncology survey in 34 countries

Lidija Kandolf Sekulović, Jun Guo, Sanjiv S. Agarwala et al. · European Journal of Cancer · 2018 · 52 citations · Full text

Melanoma World Society, Medicine, Metastatic Melanoma Worldwide +7

Cutaneous melanoma in Latin America: the need for more data

Rafael Schmerling, Dora Loria, Gabriela Cinat et al. · Revista Panamericana de Salud Pública · 2011 · 49 citations · Full text